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Background/aim: To evaluate psychological parameters and health quality profiles in women with reproductive polycystic ovary
syndrome (PCOS) phenotypes and age matched controls.
Materials and methods: The study groups included 101 women with PCOS (54 with the National Institutes of Health [NIH] phenotype
and 47 with the non-NIH phenotype) and 49 healthy female controls. The participants completed anxiety and depression scales and
four quality of life domains.
Results: We identified the women with PCOS as having a 3.39 times increased risk for depression (subscale ≥ 7) and a 3.64 times
increased risk for anxiety (subscale ≥ 10) compared to the controls. Both NIH and non-NIH phenotypes showed similar rates of
depression (46.3% vs. 46.8%, respectively; P = 0.57) and anxiety (31.5% vs. 36.2%, respectively; P = 0.47). Regarding the quality of
life scale, the women with NIH PCOS had significantly lower mental health scores compared to those with non-NIH PCOS (P =
0.03). Furthermore, while mental health scores were similar in the women with PCOS and the controls, physical health scores were
significantly lower in the women with PCOS (P = 0.007).
Conclusion: Nearly half of the women with PCOS had higher depression scores and one third had higher anxiety scores. Thus,
psychiatric evaluations appear necessary for PCOS patients in order to diagnose and treat clinical depression and anxiety.
Key words: Anxiety, depression, polycystic ovary syndrome, phenotype, quality of life

1. Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in reproductive-aged women, affecting
6–10% of women (1). The major reproductive features
of PCOS include menstrual irregularity, anovulation,
androgen excess symptoms, and infertility. However,
many women with PCOS also have metabolic conditions
including abdominal obesity, glucose intolerance,
dyslipidemia, and elevated blood pressure. Furthermore,
women with PCOS are at an increased risk for
cardiovascular events. Recent studies have also indicated
that women with PCOS have an increased prevalence
for mood disorders (2). Especially symptoms such as
hirsutism, acne, abdominal obesity, and subfertility might
cause a reduction in self-esteem and sexual satisfaction
and deterioration in quality of life (QoL). Although the
exact etiology of the increased rate of mood disorders
remains unknown, each of these factors might be
* Correspondence: drsezert@gmail.com
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speculated to cause emotional distress and psychological
burden in young women with PCOS (3).
PCOS is a heterogeneous disease and, to date, several
criteria had been introduced for its diagnosis. In 1990,
PCOS was defined by the National Institutes of Health
(NIH) criteria as requiring both the presence of menstrual
irregularity and hyperandrogenism (4). In subsequent
years, it was noted that women with PCOS might also
present with a milder phenotype. Thus, the Rotterdam
criteria were introduced in 2003, and now there are nonNIH phenotypes, such as normoandrogenic or ovulatory
women with PCOS, who have also been included in the
spectrum of this disease (5,6). In line with the recent
guidelines, gynecologists and endocrinologists suggest
the use of the Rotterdam criteria (1–7). Therefore, both
women with mild phenotypes and those with the classic
NIH phenotype are now evaluated together regarding
reproductive, metabolic, and psychiatric problems.
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Previous studies have illustrated that women diagnosed
with the NIH criteria had more cardiovascular risk factors
compared to those with the non-NIH PCOS phenotypes
(8–11). However, the association is not yet clarified as to
whether the NIH and non‑NIH phenotypes have similar
risks regarding mood disorders and impaired QoL profiles
(12). As far as we know, the most commonly reported
psychiatric co-morbidity of PCOS women was depression
and anxiety disorders. PCOS women presenting with
these physical and psychiatric symptoms might also
have impaired QoL profiles. Klimczak et al. also reported
that, irrespective of phenotype, PCOS patients with high
levels of androgens and lipids were at the increased risk
for depression (13). PCOS patients presenting with
hyperandrogenic symptoms might also have impaired
QoL profiles.
Therefore, we aimed to assess the psychological
parameters (depression and anxiety disorder) and QoL
parameters in different phenotypes (NIH and non-NIH)
of women with PCOS and healthy controls. The secondary
aim was to analyze the impact of sociodemographic and
reproductive features on depression in women with PCOS.
2. Materials and methods
2.1. Patients
This cross-sectional study was conducted in a specialized
reproductive endocrinology clinic of a tertiary care center
from January 2014 to July 2014. The study group included
women aged 18–35 years who were newly diagnosed with
PCOS (PCOS group). Patients for the control group were
recruited from women who underwent routine gynecologic
examinations during the same period (non-PCOS group).
Women with other causes of hyperandrogenism such
as congenital adrenal hyperplasia, Cushing syndrome
and androgen producing tumor, diabetes mellitus,
hypertension, thyroid dysfunction, history of psychiatric
disease, and use of steroids, oral contraceptives, and other
medications during the previous 3 months were excluded.
The hospital’s local ethical committee approved this
study and all participants gave their written informed
consent prior to participation. All women who presented
with the complaint of irregular menses or hirsutism
had undergone the routine complete PCOS work-up.
Participants who were confirmed to have PCOS according
to the Rotterdam criteria were invited to participate in
the trial. Women who were enrolled in the study were
classified into two phenotypes by the two specialists (SA,
FA) in this study. The two phenotypes included: 1) NIH
phenotype: irregular cycles (O) and hyperandrogenism
(H) with or without polycystic ovaries (P) (O + H + P and
O + H); and 2) non-NIH phenotype: ovulatory phenotype
with hyperandrogenism, polycystic ovaries, and regular
cycles (H + P), or normoandrogenic phenotype: oligo-

anovulation, polycystic ovaries, and normal androgen
levels (O + P). Upon being accepted into this study, all
women were asked to complete a data collection form to
identify their sociodemographic and clinical features.
2.2. Clinical and biochemical assessments
All participants gave fasting venous blood samples in the
early follicular period of the menstrual cycle. They were
also analyzed for fasting glucose (FG), follicle stimulating
hormone (FSH), luteinizing hormone (LH), thyroid
stimulating hormone (TSH), prolactin (PRL), total
testosterone (TT), and dehydroepiandrosterone acetate
(DHEAS). All participants were weighed in the morning
with light clothes and the body mass index (BMI) was
calculated with the following formula: BMI = weight
(kg)/height squared (m2). Waist circumference (WC) was
measured at the level of the midpoint between the lowest
rib and the iliac crest.
2.3. Psychiatric assessment
The Hospital Anxiety and Depression Scale (HADS) is a
reliable self-assessment scale specifically developed for
detecting states of depression and anxiety in the setting of
a hospital outpatient clinic. The scale comprises of 14 items
consisting of HADS-A (anxiety, 7 questions) and HADS-D
(depression, 7 questions) subscales. All items are rated
on a four-point scale, from 0 to 3, resulting in maximum
subscale scores of 21, with higher scores indicating greater
levels of depression and anxiety. Aydemir et al. (14)
previously established the validity and reliability of the
Turkish version of this scale and determined cut-off points
for the depression subscale and anxiety subscale as 7/8 and
10/11, respectively.
The World Health Organization Quality of Life
(WHOQOL) - BREF is a shorter version of the original
QoL questionnaire developed by the WHO. This scale
has 26 items with a five-point Likert-type response for
generic quality of life (QoL assessments with four broad
domains, namely physical, mental, social relations,
and environmental) (15,16). The instrument assesses
satisfaction with life as well as the impact of disease or
illness, and it captures positive and negative aspects of
QoL. It was validated for the Turkish population by Eser
et al. (17).
2.4. Statistical analysis
Statistical analysis was performed using SPSS 22.0 (IBM
Statistics for Windows, IBM Corporation, Armonk, NY,
USA) and P < 0.05 was considered statistically significant.
Normal distribution of the data in the groups was tested
with Kolmogorov–Smirnov tests. Variables were expressed
as mean ± standard error for normally distributed data
and proportions for the nonnormally distributed and
categorical data. The differences in parametric and
categorical variables were tested with Student’s t-tests and
Pearson chi-square tests, respectively. When investigating
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the changes in variables by different groups, the effect of
age and BMI was adjusted using analysis of covariance
(ANCOVA) tests and logistic regression analyses. The
power analysis of the study was done with reference
to a previous study (18) that reported the differences in
anxiety scores as 2.9 ± 3.5 and depression scores as 2.4 ±
3.2. The current study was sufficiently powered to detect
the differences in anxiety between NIH and non-NIH
phenotypes of PCOS (93.42% power, effect size = 0.71),
the differences in depression between NIH and non-NIH
PCOS phenotypes (80.33% power, effect size = 0.55),
and the difference between PCOS and controls (80.15%
power, effect size = 0.30).
3. Results
3.1. Patients’ characteristics
A total of 172 patients were eligible for this study. Patients
were excluded if they had a positive pregnancy test (n = 3),
had used any hormonal and insulin sensitizing medication
within the previous 3 months (n = 4), or had missing
data (n = 15). The remaining 150 women were enrolled

in the study for final analysis. The study group ultimately
included 101 women with PCOS (n = 54 women with
NIH, and n = 47 women with non-NIH phenotype) and
the control group included 49 women without PCOS.
The demographic and endocrinologic features of the
participants are shown in Table 1.
3.2. Comparison of depression and anxiety statuses in
the study and control groups (PCOS vs. non-PCOS)
When the depression and anxiety scores were compared,
women with PCOS had significantly higher HADS-D and
HADS-A scores compared to the controls (P < 0.001 and
P = 0.001, respectively). According to HADS, the cutoff values for the depression and anxiety subscales are 7
and 10 points, respectively. By using these HADS cut-off
values, the rates of depression and anxiety among women
with PCOS were also significantly higher than those of
the controls (46.5% vs. 20.0%; P = 0.002 and 33.7% vs.
12.2%; P = 0.005, respectively) (Table 2). Compared to the
controls, the women with PCOS had a 3.39 times higher
risk of depression (P = 0.005) and a 3.64 times higher risk
of anxiety (P = 0.002).

Table 1. The demographic and endocrinologic characteristics of women with different PCOS phenotypes and controls.
PCOS with NIH
phenotype

PCOS with nonNIH phenotype

Control group
(C)

P value
(NIH vs. non-NIH)

P value (PCOS vs. C)
(age/BMI adjusted)

Age (years)

24.70 ± 4.39

24.15 ± 4.08

26.29 ± 5.17

0.514

0.022

BMI (kg/m2)

25.84 ± 4.81

23.88 ± 8.45

24.44 ± 3.88

0.399

0.021

WC (cm)

89.29 ± 11.80

83.73 ± 14.31

80.27 ± 11.67

0.055

<0.001

FG score

14.00 ± 3.00

7.00 ± 7.00

6.00 ± 2.00

<0.001

<0.001

Fasting glucose (mg/dl)

84.00 ± 11.00

82.00 ± 9.00

85.00 ± 8.00

0.276

FSH (IU/L)

5.50 ± 2.25

5.80 ± 1.90

6.49 ± 1.38

0.203

0.196
0.076

LH (IU/L)

7.60 ± 6.30

6.25 ± 9.20

4.10 ± 2.11

0.635

E2 (pg/mL)

41.00 ± 23.00

41.50 ± 24.30

41.10 ± 13.76

0.29

PRL (ng/mL)

12.15 ± 7.45

13.00 ± 6.90

13.00 ± 4.60

0.574

TSH (µIU/mL)

1.90 ± 1.10

1.90 ± 1.10

1.99 ± 0.89

0.669

Testosteron (ng/mL)

0.75 ± 0.19

0.62 ± 0.20

0.46 ± 0.14

<0.001

DHEAS (µmol/L)

263.0 ± 115.0

207.0 ± 120.0

180.0 ± 76.0

0.016

<0.001

Clinical HA n (%)

48 (88.9)

26 (55.3)

14 (28.6)

<0.001

<0.001

Biochemical HA n (%)

54 (100)

15 (31.9)

12 (24.5)

<0.001

<0.001

<0.001
0.410
0.406
0.520
<0.001

Data are shown as mean ± SD or number (percentage). Continuous data were analyzed with independent t-test with adjustment for age/
BMI for all variables except the age and BMI variables. Categoric data were assessed with chi-square test. 1Data are presented as mean
± SEM and 2column percentage. NIH, National Institute of Health; BMI, body mass index; WC, waist circumference; FG, Ferriman–
Gallwey; FSH, follicle stimulating hormone; LH, luteinizing hormone; E2, estradiol; PRL, prolactin; TSH, thyroid stimulating hormone;
DHEAS, dehydroepiandrostenedione sulfate; HA, hyperandrogenism
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Table 2. Comparison of depression and anxiety status in women with different PCOS phenotypes and the controls.
NIH PCOS

Non-NIH
PCOS

P value (NIH
Control
vs. non-NIH)

PCOS

P value
(PCOS vs. control)

7.00 ± 3.25

7.00 ± 4.00

0.67

6.00 ± 2.00

7.00 ± 4.00

<0.001

Rate of depression (n%)

25 (46.3)

22 (46.8)

0.96

10 (20.4)

47 (46.5)

0.002

HADs-A scores

10.00 ± 4.00

10.00 ± 4.00

0.47

8.00 ± 3.00

10.00 ± 5.00

0.001

17 (31.5)

17 (36.2)

0.62

6 (12.2)

34 (33.7)

0.005

Parameters
HADs-D scores1
2

1

Rate of anxiety2 (n%)

Data are shown as mean ± SD or number (percentage). Continuous data were analyzed with independent t-test with adjustment for age/
BMI for all variables except the age and BMI variables. Categoric data were assessed with chi-square test. 1Data are presented as mean
± SEM and 2column percentage. NIH, National Institute of Health; HADs-D, Depression subscale of hospital anxiety and depression
scale; HADs-A, Anxiety subscale of hospital anxiety and depression scale. HADS-D ≥ 10 was used to suggest depression and HADS-A
≥ 7 was used to suggest anxiety disorder.

3.3. Comparison of the depression and anxiety statuses
in different PCOS phenotypes (NIH vs. non-NIH)
The depression and anxiety scores were specifically
assessed for the women with PCOS. When we compared
these scores between the subgroups of women with PCOS
with NIH and non-NIH phenotypes, the mean HADS-D
and HADS-A scores were similar in the two groups (P =
0.67 vs. P = 0.47, respectively). Accordingly, by using the
HADS cut‑off value, the rates of depression and anxiety
were also similar in NIH and non‑NIH PCOS phenotypes
(46.3% vs. 46.8%, P = 0.96 and 31.5% vs. 36.0%, P = 0.62,
respectively) (Table 2).
3.4. The comparison of QoL in women with PCOS and
controls, and between the NIH and non-NIH phenotypes
For the QoL scores, mental, social, and environmental
domain scores were similar in the women with PCOS and
the controls (P = 0.11, P = 0.75, and P = 0.92, respectively).
However, physical health domain scores were significantly
lower in the women with PCOS compared to the controls
(P = 0.007). When the phenotypes were compared, there
was no difference in physical, social, and environmental

domain scores between NIH and non-NIH phenotypes
(P = 0.82, P = 0.89, and P = 1.0, respectively). However,
mental health domain scores were significantly lower in
NIH phenotypes compared to non-NIH phenotypes (P =
0.03) (Table 3).
3.5. Regression analysis for anxiety and depression in
women with PCOS
In the univariate analysis, all of the sociodemographic,
clinical, and endocrinological variables were similar in the
two groups of PCOS women (n = 101) who were depressed
and not depressed (Table 4). Similarly, regression analysis
for anxiety and depression also revealed no independent
predictor for anxiety in PCOS women (data not shown).
4. Discussion
In this study, we investigated the psychological statuses
and QoL profiles in women with different phenotypes of
PCOS and healthy controls. We found that almost half of
the PCOS women had higher scores for depression and
one third had higher scores for anxiety. This relatively
high prevalence for higher depression scores was

Table 3. Comparison of quality of life scores, assessed by WHOOL-Bref in women with different PCOS phenotypes and the controls.
Domains of
WHOQOL-Bref scale

NIH PCOS

Non-NIH
PCOS

P value (NIH
vs. non-NIH)

Control

Physical domain scores

22.56 ± 3.61

22.72 ± 3.62

0.82

24.37 ± 3.71 22.64 ± 3.60

0.007

Mental domain scores

20.04 ± 3.85

21.55 ± 3.01

0.03

21.76 ± 3.88 20.74 ± 3.55

0.11

Social domain scores

11.02 ± 2.47

11.09 ± 2.22

0.89

11.18 ± 2.56 11.05 ± 2.35

0.75

Environmental domain scores

31.17 ± 4.50

31.17 ± 4.80

1.00

31.08 ± 5.97 31.17 ± 4.62

0.92

PCOS

P value
(PCOS vs. control)

Data are shown as mean ± SD or number (percentage). Data were analyzed with independent t-test with adjustment for age/BMI for
all variables except the age and BMI variables. 1Data are presented as mean ± SEM. NIH, National Institute of Health; WHOQOL-Bref,
World Health Organization quality of life scale
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Table 4. Sociodemographic and endocrinologic characteristics of women with PCOS according to the depression status assessed by
HADS.
Parameters

Not depressed

Depressed

P value

Age1 (years)

24.11 ± 4.04

24.83 ± 4.46

0.398

BMI (kg/m )

26.35 ± 4.91

25.9 2 ± 5.83

0.685

Presence of marriage2, n (%)

31 (57.4)

33 (70.2)

0.217

High school education2, n (%)

43 (79.6)

29 (61.7)

0.052

Employee , n (%)

14 (25.9)

15 (32.6)

0.512

27 (50)

29 (61.7)

0.316

Waist circumference ≥ 88 cm2, n (%)

23 (50)

23 (59)

0.513

FG score ≥ 8 , n (%)

34 (63)

30 (63.8)

1.000

Oligo-anovulation , n (%)

44 (81.5)

42 (89.4)

0.198

Biochemical hyperandrogenism, n (%)

39 (72.2)

30 (63.8)

0.398

Clinical hyperandrogenism, n (%)

36 (66.7)

38 (80.9)

0.121

LH/FSH1

1.22 ± 1.17

1.22 ± 1.14

0.615

TSH1 (µIU/mL)

1.99 ± 0.86

1.96 ± 0.85

0.854

PRL1 (ng/mL)

13.57 ± 6.00

13.74 ± 4.82

0.879

Testosterone (ng/mL)

0.70 ± 0.19

0.68 ± 0.175

0.639

DHEAS (µmol/L)

224 ± 94

225 ± 129

0.842

Sociodemographic parameter

1

2

2

History of infertility , n (%)
2

Clinical parameters

2

2

Biochemical parameters

1

1

Data are shown in mean ± SD or number (percentage). Data were analyzed with Student’s t-tests and chi-square test in parametric
and categoric variables. 1Data are presented as mean ± SEM and 2column percentage. BMI, body mass index; FG, Ferriman–Gallwey
score; LH, luteinizing hormone; FSH, follicle stimulating hormone; TSH, thyroid stimulating hormone; PRL, prolactin; DHEAS,
dehydroepiandrosterone sulfate.

consistent with a recent meta-analysis that reported a
fourfold increased risk of depression in PCOS women (2).
Additionally several studies have reported a wide range of
depression and anxiety levels for various populations of
PCOS women (13,19,20). Population surveys conducted
in 10 countries worldwide also reported the lifetime
prevalence of depression varied from 3.0% to 16.9%. This
high variation in depression rates in PCOS women might
be attributed to their cultural backgrounds, differences in
genetic predisposition, and the use of different scales for
psychological assessments.
Whether the incidence of depression and anxiety
differs among NIH and non-NIH PCOS women is still
unclear. To the best of our knowledge, the only study
published in the English language literature was carried
out by Moran et al., who recruited 54 women with PCOS
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and 27 controls, and no difference was reported between
the two phenotypes of PCOS (12). However, this study
was insufficiently powered to detect the difference in
depression between the PCOS phenotypes and controls.
For the first time in the literature, with a powered study,
we have demonstrated there is no difference in depression
levels between PCOS phenotypes.
PCOS is the most common endocrinopathy of
reproductive-aged women. The clinical features of this
syndrome, such as menstrual irregularity and androgen
excess symptoms, begin appearing during adolescence
and continue through the reproductive years. With
increasing age, young women with PCOS may also
suffer from infertility, abdominal obesity, and glucose
intolerance. Chronic exposure to all of these PCOS
symptoms may impair the psychiatric status and the QoL
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of these young women (22). However, not all women
presenting with all of the PCOS signs develop depression,
nor are the milder normoandrogenic phenotypes free of
these mood disorders. Bazarganipour et al. investigated
300 Iranian women with PCOS and reported that the
women with hyperandrogenism and polycystic ovaries
had higher depression and anxiety symptoms than the
other phenotypes (23). However, women with menstrual
irregularities had higher psychological impairment in
the quality of life than those with hyperandrogenism. An
earlier study by these authors also showed that menstrual
irregularities are the major concern in women with PCOS
and lead to reduced feminine identity (24).
The pathophysiology of the increased depression and
anxiety in women with PCOS is still unclear. Livadas et
al. reported that the degree of anxiety was parallel to the
degree of hyperandrogenemia and insulin resistance (25).
However, in other studies, the increased risk of depression
and anxiety among women with PCOS was attributed to
poor self-esteem linked to hirsutism, acne, and healthrelated concerns (26), rather than the clinicobiochemical
markers (27). Some studies in women have shown an
association between high serum androgen levels and
depression (28–30). On the other hand, some other studies
have failed to demonstrate any association between free
and total androgen levels with depression (31). Similarly, in
this study, we found that serum testosterone and DHEA-S
levels were not related to higher depression scores. This
leads us to think that it is the body perception as to whether
the young women are pleased with their body appearance
in the mirror that predisposes the women to depression
rather than an increased serum level of androgens.
Another study from Turkey revealed that the FG score was
an independent risk factor for depression in PCOS women
and hirsutism was the major contributor to anxiety in
the questionnaire (21). In contrast, studies from India,
Australia, and the United States did not demonstrate any
association between depression and hirsutism (12,31,32).
This difference might be explained by cultural differences
in conceptions of “beauty” or “hirsutism.” Klimczak et
al. also reported that PCOS patients with depression
demonstrated higher blood lipids than the nondepressed
ones (13). However, neither age nor BMI had an impact on
the rate of depression in women with PCOS.
QoL questionnaires (e.g., WHOQOL-BREF) also
yielded lower scores in both physical and mental fields

in PCOS patients. Although physical scores in the two
phenotypes were similar, mental scores were lower in
the NIH phenotype. In our previous study, we found a
significant inverse relationship between the FG scores and
QoL scores in infertile PCOS patients (33). Similarly, in
the current study, mental scores were also significantly
lower in PCOS patients with the NIH phenotype, in which
both clinical and biochemical hyperandrogenism were
also more common. An interpretation of these results may
be that, although the hyperandrogenism causes emotional
disturbances, and has a significant impact on the
psychological domain of the QoL, it does not always cause
psychiatric problems like depression. However, improving
the QoL is also an important issue for women with PCOS,
since 14% of women with PCOS reported suicidal ideas
(34). Current evidence suggested that psychological
distress, impaired self-esteem, negative body image, and
sexual dysfunction might be the targets to improve QoL.
Although this study has some strengths, there were
also limitations. The first limitation is that this study was
a single center study and does not represent whole PCOS
population in this country. The second limitation is the
cross-sectional study design that limits the report of a firm
conclusion. Only a prospective study design could clarify
the cause–effect relationship between mood disorders and
PCOS. Therefore, future studies should investigate the
possible etiologic factors for the development of mood
disorders in women with PCOS and should be conducted
in multiple centers in different countries and cultures.
In conclusion, we found that both depression and
anxiety scores, evaluated by HADS, are higher in women
with PCOS compared to controls. For the first time
in the literature, with a sufficiently powered study, we
demonstrated that NIH and non-NIH phenotypes have
similar rates of depression and anxiety disorders. Although
women with the NIH phenotype have lower scores in some
aspects of the QoL scale, all PCOS women, regardless of
their phenotype, might benefit from an investigation of
psychiatric co-morbidities. It is known that, compared
to family medicine physicians and general internists,
gynecologists are less likely used to evaluating psychiatric
co-morbidities. Since the majority of women with
depression might be cured with appropriate treatment,
endocrinologists and gynecologists should pay special
attention to the psychological problems of women with
PCOS and refer them to psychiatrists when necessary.
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